Pregnancy after breast cancer in BRCA1/2 mutation carriers

Research output: Contribution to journalReview articlepeer-review

Abstract

BACKGROUND: Often young women affected with BRCA1/2 positive breast cancer have not finished or even not started their childbearing before the onset of the disease. The aim of our mini-review is to summarize state of art knowledge on pregnancy after breast cancer in BRCA1/2 carriers.

METHODS: A broad review of the literature was conducted using MEDLINE (via PubMed) for relevant articles published. This review summarizes the impact of different cytotoxic agents on a fertility, fertility preservation, maternal and fetal prognosis after pregnancy in breast cancer survivors with BRCA1/2.

CONCLUSION: According to the existing literature evidence pregnancy after therapy for breast cancer in BRCA carriers is safe for the mother and offspring, but patients' needs, oncofertility counseling and fertility-sparing strategy should be carefully planned before starting the cytotoxic treatment.

Original languageEnglish
Article number3
Number of pages7
JournalHereditary Cancer in Clinical Practice
Volume20
Issue number1
DOIs
Publication statusPublished - 21 Jan 2022

Field of Science*

  • 3.1 Basic medicine
  • 3.2 Clinical medicine

Publication Type*

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database

Fingerprint

Dive into the research topics of 'Pregnancy after breast cancer in BRCA1/2 mutation carriers'. Together they form a unique fingerprint.

Cite this